Clinical trial · Observational
The Value of circRNAs (hsa_circ_0004001) in Early Diagnosis of HCC
NCT06042842CI-TRIAL-00070186unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
1. To evaluate the clinical utility of plasma circRNAs (hsa\_circ\_0004001) as a non invasive diagnostic biomarker for HCC patients and to differentiate between malignant and nonmalignant hepatic disorders. 2. To study the relation of circRNAs (hsa\_circ\_0004001) to HCC staging. 3. To compare between circRNAs (hsa\_circ\_0004001) and the routine marker (AFP) as biomarkers for HCC diagnosis.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatic Cell Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (3)
- label
- group 1
- description
- healthy control
- label
- group 2
- description
- patient with hepatic cell carcinoma
- label
- group 3
- description
- patient with non malignant liver diseased
Primary outcomes (1)
- measure
- (1) To evaluate the clinical utility of plasma circRNAs (hsa_circ_0004001)by Q-PCR as a non invasive diagnostic biomarker for HCC patients and to differentiate between malignant and nonmalignant hepatic disorders
- timeFrame
- baseline
- description
- 1. To evaluate the clinical utility of plasma circRNAs (hsa\_circ\_0004001) by Q-PCR as a non invasive diagnostic biomarker for HCC patients and to differentiate between malignant and nonmalignant hepatic disorders 2. To study the relation of circRNAs (hsa\_circ\_0004001) to HCC staging. 3. To compare between circRNAs (hsa\_circ\_0004001) and the routine marker (AFP) as biomarkers for HCC diagnosis
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. group one patients early diagnosed as HCC 2. group two patient diagnosed with chronic non-malignant liver disease 3 group three healthy control group Exclusion Criteria: 1. Patients with any other type of malignant or benign tumors should be excluded from our study. 2. History of chemotherapy or surgical treatment of cancer
References
Publications (0)
Data not yet available
No reference posted for this study.